Icon Genetics   Report issue

For profit Phase 1
Founded: Halle Germany (1999)

Organization Overview

First Clinical Trial
2010
NCT01022255
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Icon Genetics GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Follicular (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3